Key stats
About BMO ARK GENOMIC REVOLUTION FD TR UNIT
Expense ratio
0.96%
Home page
Inception date
Nov 14, 2022
The fund reaches across multiple sectors and geographies for companies that the advisor believes will benefit from innovations in the genomics-related industry. Such companies are those that may develop, produce or enable targeted therapeutics, bioinformatics, stem cells or molecular diagnostics. Using their own internal research and analysis, the adviser selects companies perceived to be capitalizing on disruptive innovation or are enabling the further development of the Genomic Revolution theme in the markets in which they operate. The adviser uses both top-down and bottom-up approaches that evaluates ESG considerations. This is a niche fund which employs an actively-managed strategy. Hence, investors should look closely at where the fund makes its bets before investing.
Classification
What's in the fund
Exposure type
Health Technology
Technology Services
Health Services
Stock breakdown by region